Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia
Subcutaneous on par with IV pembrolizumab for NSCLC
17 Jul 2025
bởiStephen Padilla
Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.
Subcutaneous on par with IV pembrolizumab for NSCLC
17 Jul 2025
RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals
16 Jul 2025
bởiMike Ng
A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.
